NEW YORK (360Dx) – Becton Dickinson said today that it has received 510(k) clearance from the US Food and Drug Administration for an automated flow cytometer system with a Leucocount reagent assay used in residual white blood cell enumeration.
The BD FACSVia system enables identifying and counting of rWBCs in leucoreduced blood products when it's used with the BD Leucocount kit and BD Trucount tubes, the firm said.
BD Biosciences President John Ledek noted that the system provides blood banks and clinical laboratories with an easy way to determine and quantify the presence of residual white blood cells.
"The addition of the BD FACSVia system follows our larger strategy of making flow cytometry easier to use with improved efficiency, simplified sample analysis, and high-quality diagnostic results," he added.
BD said that the new system improves overall lab efficiency and simplifies workflow, and its design is compact so that it can easily fit on a benchtop or within a hood.